1
|
Prenatal diagnosis of rhabdoid tumor: Ultrasound, magnetic resonance imaging, 3D reconstruction and review of the literature. J Gynecol Obstet Hum Reprod 2022; 51:102479. [DOI: 10.1016/j.jogoh.2022.102479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Accepted: 09/20/2022] [Indexed: 11/18/2022]
|
2
|
Zhen L, Gu CM, Han J, Pan M, Li DZ. Tumor markers in cord blood: A predictor of fetal malignant neoplasm? Eur J Obstet Gynecol Reprod Biol 2021; 263:280-281. [PMID: 34134923 DOI: 10.1016/j.ejogrb.2021.05.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 05/28/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Li Zhen
- Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
| | - Cong-Min Gu
- Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
| | - Jin Han
- Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
| | - Min Pan
- Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
| | - Dong-Zhi Li
- Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China.
| |
Collapse
|
3
|
Schenone CV, King A, Castro E, Ketwaroo P, Donepudi R, Sanz-Cortes M. Prenatal detection of disseminated extrarenal malignant rhabdoid tumor with placental metastases. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2021; 57:1008-1010. [PMID: 32621313 DOI: 10.1002/uog.22136] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 06/12/2020] [Accepted: 06/19/2020] [Indexed: 06/11/2023]
Affiliation(s)
- C V Schenone
- Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, TN, USA
| | - A King
- Department of Pediatric Surgery, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA
| | - E Castro
- Department of Pathology and Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA
| | - P Ketwaroo
- Edward B. Singleton Department of Radiology, Division of Fetal and Neonatal Imaging, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA
| | - R Donepudi
- Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Fetal Center, Houston, TX, USA
| | - M Sanz-Cortes
- Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Fetal Center, Houston, TX, USA
| |
Collapse
|
4
|
Nemes K, Clément N, Kachanov D, Bens S, Hasselblatt M, Timmermann B, Schneppenheim R, Gerss J, Siebert R, Furtwängler R, Bourdeaut F, Frühwald MC. The extraordinary challenge of treating patients with congenital rhabdoid tumors-a collaborative European effort. Pediatr Blood Cancer 2018; 65:e26999. [PMID: 29418059 DOI: 10.1002/pbc.26999] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Revised: 12/21/2017] [Accepted: 01/02/2018] [Indexed: 12/25/2022]
Abstract
BACKGROUND Congenital rhabdoid tumors are rare and highly aggressive malignancies. In general, patients are considered to be incurable and are often treated using an exclusive, primarily palliative approach. METHODS A prospective and retrospective collection of 42 patients from the European Rhabdoid Registry (EU-RHAB), France and Moscow (2006-2016) diagnosed within the first 28 days of life was evaluated. Genetic and clinical reference evaluation included SMARCB1 and/or SMARCA4 (fluorescence-in-situ-hybridization, multiplex ligation-dependent probe amplification, and sequencing) mutation analysis and immunohistochemistry. Forty-eight percent (20/42) of patients were treated according to the EU-RHAB therapy, 7% (3/42) according to the pilot approach Rhabdoid 2007, 33% (14/42) with individual schedules, and 12% (5/42) received no chemotherapy at all. RESULTS Forty point five percent (17/42) of patients presented with extracranial rhabdoid tumors, 33.5% (14/42) with rhabdoid tumors of the central nervous system (atypical teratoid/rhabdoid tumor), and the remainder 26% (11/42) demonstrated synchronous tumors. Metastases at diagnosis were present in 52% (22/42) of patients. A germline mutation was detected in 66% (25/38) and was associated with a poor prognosis (4.2 ± 4.1% vs. 48 ± 16.4%, P < 0.00005). A gross total resection (GTR) was realized in 17%. A GTR (42.9 ± 18.7% vs. 4.9 ± 4.3%, P = 0.04), therapy according to a standardized approach (20.9 ± 8.7% vs. 7.1 ± 6.9 %, P = 0.0018), and a complete remission (CR) (23.6 ± 9.8% vs. 1.3 ± 3.6%, P = 0.04) were significant prognostic factors. CONCLUSIONS The management of patients with congenital rhabdoid tumors requires a major multidisciplinary effort. In many instances, cure is not possible and a palliative approach is warranted. Our data indicate a positive impact of standardized therapeutic approaches on survival, making a tailored approach toward affected patients and their families mandatory.
Collapse
Affiliation(s)
- Karolina Nemes
- Swabian Children's Cancer Center, Children's Hospital, Klinikum Augsburg, Augsburg, Germany
| | - Nathalie Clément
- Pediatric care and research Center, Institute Curie, PSL Research University, Paris, France
| | - Denis Kachanov
- National Scientific and Practical Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev, Moscow, Russian Federation
| | - Susanne Bens
- Institute of Human Genetics, University of Ulm & University Hospital of Ulm, Ulm, Germany
| | - Martin Hasselblatt
- Institute of Neuropathology, University Hospital Muenster, Muenster, Germany
| | - Beate Timmermann
- Clinic for Particle Therapy, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
| | - Reinhard Schneppenheim
- Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Joachim Gerss
- Institute of Biostatistics and Clinical Research, University of Münster, Muenster, Germany
| | - Reiner Siebert
- Institute of Human Genetics, University of Ulm & University Hospital of Ulm, Ulm, Germany
| | - Rhoikos Furtwängler
- Department of Pediatric Oncology and Hematology, Saarland University of Hospital Saarland, Saarland, Germany
| | - Franck Bourdeaut
- Pediatric care and research Center, Institute Curie, PSL Research University, Paris, France
| | - Michael Christoph Frühwald
- Swabian Children's Cancer Center, Children's Hospital, Klinikum Augsburg, Augsburg, Germany.,Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, University of Muenster, Muenster, Germany
| | | |
Collapse
|
5
|
Ultrasound Presentation of a Disseminated Fetal and Neonatal Rhabdoid Tumor. Case Rep Obstet Gynecol 2018; 2018:6073204. [PMID: 29670784 PMCID: PMC5833875 DOI: 10.1155/2018/6073204] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2017] [Accepted: 01/08/2018] [Indexed: 12/18/2022] Open
Abstract
This is a case report of a disseminated fetal rhabdoid tumor discovered at 32 weeks of gestation in a 29-year-old woman on immunosuppressive therapy. The mother consulted for a decrease in fetal movement. Fetal ultrasound showed signs of a disseminated tumor affecting the left armpit, liver, spleen, and limbs. A caesarian section was performed because of signs of fetal distress. Immunohistochemical analysis of a fetal biopsy showed deletion of the SMARCB1 gene. Pathological analysis of the placenta showed a rhabdoid tumor invading both fetal and maternal compartments. The mother underwent a whole-body MRI, and no metastasis was found. To the best of our knowledge, this is the first report of a disseminated rhabdoid tumor invading both fetal and maternal compartments.
Collapse
|
6
|
Stolten M, Betrand K, Lotterman C, Warrier R. Neonate With Paraplegia. Clin Pediatr (Phila) 2016; 55:199-201. [PMID: 26170276 DOI: 10.1177/0009922815595063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
| | - Kelsey Betrand
- University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA, USA
| | | | - Raj Warrier
- Ochsner Medical Center for Children, New Orleans, LA, USA
| |
Collapse
|
7
|
Boudjemaa S, Petit A, Dainese L, Bourdeaut F, Lipsett J, Coulomb A. Congenital Disseminated Extrarenal Malignant Rhabdoid Tumor. Pediatr Dev Pathol 2015; 18:401-4. [PMID: 25751458 DOI: 10.2350/14-07-1533-cr.1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Soft tissue tumors arising in association with genetic or malformation syndromes have been increasingly reported. Malignant rhabdoid tumor (MRT) is a highly aggressive neoplasm of infancy and young childhood, characterized by typical morphology and biallelic inactivation of the SMARCB1 (INI1/hSNF5/BAF47) gene on chromosome 22q.2 which encodes a subunit of the SWI/SNF ATP-dependent chromatin remodeling complex. Congenital infantile disseminated MRT represents a unique clinicopathologic presentation of this tumor. We report a case occurring in a female neonate who presented at birth a voluminous left thigh mass. Surgical biopsy performed at day 9 showed morphology and immunoprofile of MRT. Staging evaluation identified hypercalcemia and distant nodules. The mass showed rapid growth. Despite chemotherapy, the tumor progressed with exteriorization through the biopsy scar. Chemotherapy was discontinued and treatment limited to palliative care and the child died on day 51. The tumor was homozygous for the SMARCB1 deletion with apparent de novo heterozygous germ line deletion in the infant, not identified in the parents.
Collapse
Affiliation(s)
- Sabah Boudjemaa
- 1 Service d'Anatomie et de Cytologie Pathologiques, Hôpital d'Enfants Armand Trousseau, 26 Avenue du Dr Arnold Netter, 75571 Paris Cedex 12, France, and Université Pierre et Marie Curie, Paris 6, France
| | - Arnaud Petit
- 3 Service d'Oncohématologie Pédiatrique, Hôpital d'Enfants Armand Trousseau, 26 Avenue du Dr Arnold Netter, 75571 Paris Cedex 12, France
| | - Linda Dainese
- 1 Service d'Anatomie et de Cytologie Pathologiques, Hôpital d'Enfants Armand Trousseau, 26 Avenue du Dr Arnold Netter, 75571 Paris Cedex 12, France, and Université Pierre et Marie Curie, Paris 6, France
| | - Franck Bourdeaut
- 4 Département de Pédiatrie et INSERM U830, Institut Curie, 26 rue d'Ulm, 75248 Paris Cedex, France
| | - Jill Lipsett
- 2 SA Pathology, Women's and Children's Hospital, 72 King Hospital Rd, North Adelaide, South Australia 5006, Australia
| | - Aurore Coulomb
- 1 Service d'Anatomie et de Cytologie Pathologiques, Hôpital d'Enfants Armand Trousseau, 26 Avenue du Dr Arnold Netter, 75571 Paris Cedex 12, France, and Université Pierre et Marie Curie, Paris 6, France
| |
Collapse
|
8
|
Negahban S, Nagel I, Soleimanpour H, Aledavood A, Bagheri N, Paydar M, Daneshbod K, Hasselblatt M, Gesk S, Siebert R, Daneshbod Y. Prenatal Presentation of a Metastasizing Rhabdoid Tumor With Homozygous Deletion of the SMARCB1 Gene. J Clin Oncol 2010; 28:e688-91. [DOI: 10.1200/jco.2010.29.9735] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Shahrzad Negahban
- Institute of Pathology, Dr Daneshbod Pathology Laboratory, Shiraz, Iran
| | - Inga Nagel
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
| | | | - Azita Aledavood
- Institute of Pathology, Dr Daneshbod Pathology Laboratory, Shiraz, Iran
| | - Neda Bagheri
- Institute of Pathology, Dr Daneshbod Pathology Laboratory, Shiraz, Iran
| | - Mehdi Paydar
- Institute of Obstetrics and Fetal Medicine, Shiraz, Iran
| | - Khosrow Daneshbod
- Institute of Pathology, Dr Daneshbod Pathology Laboratory, Shiraz, Iran
| | - Martin Hasselblatt
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| | - Stefan Gesk
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
| | - Reiner Siebert
- Institute of Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Kiel, Germany
| | - Yahya Daneshbod
- Institute of Pathology, Dr Daneshbod Pathology Laboratory, Shiraz, Iran
| |
Collapse
|
9
|
Isaacs H. Fetal and neonatal rhabdoid tumor. J Pediatr Surg 2010; 45:619-26. [PMID: 20223330 DOI: 10.1016/j.jpedsurg.2009.12.011] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2009] [Revised: 12/14/2009] [Accepted: 12/14/2009] [Indexed: 12/21/2022]
Abstract
PURPOSE Few studies have focused on the behavior of rhabdoid tumor (RT) in the fetus and neonate. The purpose of this review is to show that perinatal RTs are associated with unusual findings and a poor prognosis. METHODS The author conducted a 40-year systematic review of the literature. Clinical presentation, pathology, management, and outcome of 72 fetuses and neonates with RTs are discussed. RESULTS Seventy-two fetuses and neonates presented with RTs detected prenatally (n = 12) and during the neonatal period (n = 60). The review consisted of 3 main groups: extrarenal noncentral nervous system (CNS) RT, renal RT, and CNS RT. There were some group differences in survival: extrarenal non-CNS RT (3/33 or 9.1%), renal RT (2/27 or 7.4%), and CNS RT (2/12 or 16.7%). Metastatic RT was present at diagnosis in more than half the patients (41/72 or 57%) who had a survival of 2.3%. The overall survival was 9.7%. For statistical results, there was no significant difference in survival among the 3 groups by type of tumor (P = .692). chi(2) analysis for survival with and without metastases was not valid due to small sample size. CONCLUSIONS The review shows that extrarenal RT was more common than either renal RT or CNS RT groups that is different than that observed in older individuals. Concomitant brain tumors were found in almost a third of fetuses and neonates. The CNS involvement occurred more often in patients with renal RT than in those with extrarenal RT. Metastatic disease at diagnosis was noted in more than half of the patients. Higher stage and presence of a CNS tumor were significant determinants in survival.
Collapse
Affiliation(s)
- Hart Isaacs
- Department of Pathology, Rady Children's Hospital San Diego, San Diego, CA 92123, USA.
| |
Collapse
|